01/19/23 7:00 AMNYSE : NVRO conferencesearningsNevro to Report Fourth Quarter and Full-Year 2022 Financial ResultsA live webcast of this event, as well as an archived recording, will be available in the Investors section of Nevro's website at www.nevro.com. Nevro routinely posts information that may be important to investors in the "Investor Relations" section of its website at www.nevro.com. The company encourages investors and potential investors to consult the Nevro...RHEA-AIneutral
01/12/23 7:00 AMNYSE : NVRO Nevro to Highlight New Clinical Evidence at the 2023 North American Neuromodulation Society (NANS) 26th Annual MeetingNevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced a series of data presentations supporting the use of the company's HFX™ 10 kHz TherapyRHEA-AIneutral
01/09/23 6:00 AMNYSE : NVRO Nevro Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2022 Revenue and Provides Full-Year 2023 Revenue GuidanceNevro Corp. (NYSE: NVRO),RHEA-AIpositive
12/19/22 4:05 PMNYSE : NVRO conferencesNevro to Present at 41st Annual J.P. Morgan Healthcare ConferenceNevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D.RHEA-AIneutral
12/14/22 7:00 AMNYSE : NVRO clinical trialNevro Announces Two Presentations from SENZA-PDN and SENZA-NSRBP Clinical Trials Have Been Accepted for Late-Breaking Abstract Sessions at NANS 2023 Annual MeetingNevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive,RHEA-AIneutral
11/02/22 4:05 PMNYSE : NVRO earningsNevro Reports Third Quarter 2022 Financial Results, Narrows Full-Year 2022 Guidance and Raises Revenue Contribution from Painful Diabetic NeuropathyNevro Corp. (NYSE: NVRO), delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its financial results for the third quarter ended September 30, 2022, narrowed its full-year 2022 guidance and raised itsRHEA-AIpositive
10/12/22 6:13 PMNYSE : NVRO fda approvalNevro Announces FDA Approval of HFX iQ™ Spinal Cord Stimulation System to Personalize the Treatment of Chronic PainNevro Corp. (NYSE: NVRO), a global medical device company that is deliveringRHEA-AIvery positive
10/10/22 7:00 AMNYSE : NVRO Nevro Comments on UnitedHealthcare Medical Coverage Policy UpdateNevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that on October 1, 2022, UnitedHealthcare ("United") released an update to itsRHEA-AIneutral
10/05/22 7:00 AMNYSE : NVRO conferencesearningsNevro to Report Third Quarter 2022 Financial ResultsNevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, todayRHEA-AIneutral
10/04/22 4:05 PMNYSE : NVRO fda approvalNevro Announces FDA Approval of Costa Rica Manufacturing OperationsNevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced today that the U.S. Food and Drug Administration (FDA) has approved its manufacturingRHEA-AIvery positive